Today, I revisited BEAM Therapeutics and noted institutional investors increasing their positions! Here's the lowdown!

Quite a few funds besides Peregrine (17% this month) boosted their positions in BEAM Therapeutics in the last ~3 months. 

The biggest disclosed step-ups were by FMR LLC (Fidelity) and ARK Investment Management, both via fresh 13G/A filings in August 2025. I’ve also included several smaller 13F increases.

Notable increases in the past ~3 months

• FMR LLC (Fidelity) filed a 13G/A on Aug 6, 2025, lifting its stake to 15.00% (15,083,498 sh)—a large increase from prior. Fintel

• ARK Investment Management filed a 13G/A on Aug 7, 2025, lifting to 10.35% (10,410,137 sh). Fintel

• Legal & General Group Plc (13F, filed Aug 12, 2025) reported 102,646 sh, up +8.48% q/q. Fintel

• VanEck Associates (13F, filed Aug 14, 2025) reported 1,451 sh, up +11.27% (tiny but technically an increase). Fintel

• AMG National Trust Bank (13F, filed Aug 4, 2025) reported 17,007 sh, up +289% q/q. Fintel

(And yes, Peregrine Investment Management disclosed a +17.8% increase (to 264,260 sh) in its latest 13F, covered by MarketBeat on Sept 24, 2025. ) MarketBeat

Note: 13G/A stakes (FMR, ARK) are the cleanest % of shares-out data. 13F changes indicate direction q/q but do not include exact ownership % of the company and lag by up to ~45 days.

“All” institutional investors & their % stakes

There are roughly ~455 institutional holders on record for BEAM. Publishing all of them (with % stakes) doesn’t fit here, but below are the principal holders with the best available % figures from recent filings. For >5% owners, I use the 13G/A numbers (most authoritative for company %); for others I cite aggregated holder pages that estimate % of shares outstanding.

Top institutional holders (latest reported % of shares outstanding):

• FMR LLC (Fidelity) — 15.00% (13G/A, Aug 6, 2025). Fintel

• ARK Investment Management LLC — 10.35% (13G/A, Aug 7, 2025). Fintel

• Farallon Capital Management — ~9.99% (13G/A, May 13, 2025; still current in Fintel roster). Fintel

• The Vanguard Group, Inc. — ~9.88% (aggregator snapshot). Investing.com

• BlackRock, Inc. — ~8.14% (aggregator snapshot). Investing.com

• State Street Global Advisors — ~3.70% (aggregator snapshot). Investing.com

• Arch Venture Partners — ~4.62% (aggregator snapshot; also on Fintel 13D/G roster). Investing.com+1

• Amova Asset Management — ~4.81% (aggregator snapshot). Investing.com

• Farallon Healthcare Partners — ~5.87% (aggregator snapshot). Investing.com

• Bellevue Asset Management — ~2.94% (aggregator snapshot). Investing.com

• T. Rowe Price Group — ~2.49% (aggregator snapshot). Investing.com

For the full institutional roster (hundreds of entries) with adds/cuts and effective dates, Fintel’s BEAM ownership page is the most complete live index and shows both the headline owner count (~455) and recent filings; many details beyond the top tier are behind their login/paywall. Fintel

Ed Note:

We have also increased our position in BEAM in September!

Related Articles:

BEAM Therapeutics getting closer to FDA approvals for cutting edge therapies

Cabaletta Bio $CABA might just be that "needle in the haystack" of Microcap BioTechs poised for greater things

• Here’s a fresh, single-page style investment/business report on Cabaletta Bio (NASDAQ: CABA) that pulls in the August–September 2025 filings, company updates, and the latest clinical/CMC details. 

  
  
  

  1) Institutional holders — latest Schedule 13G/13G-A cluster (summer 2025)

  Notes: figures below come from each filer’s Schedule 13G/13G-A (event date generally June 30, 2025; filings landed Aug 6–14, 2025, unless noted). Do not add Prudential (PFI) on top of Jennison (PFI is the parent; overlapping exposure). Percentages use each filer’s own denominator and blocker math where applicable.

  Holder (form)	Reported shares / power	% of class	Filed
  Jennison Associates LLC (IA)	10,107,167	7.2%	Aug 6, 2025. Cabaletta Bio, Inc.
  Alyeska Investment Group, L.P. (+ GP & Anand Parekh)	8,904,367 (shared vote/dispo; includes warrants)	9.9%	Aug 14, 2025. Cabaletta Bio, Inc.+1
  Bain Capital Life Sciences Opportunities III, L.P.	9,677,125 (incl. exercisable portion of warrants; 9.99% blocker)	9.99%	Aug 14, 2025. Cabaletta Bio, Inc.+1
  Adage Capital (ACM/ACP; Gross & Atchinson)	9,002,580 (incl. 172,822 via warrants)	9.99%	Aug 12, 2025. Cabaletta Bio, Inc.+2Cabaletta Bio, Inc.+2
  Citadel (Advisors entities & Securities)	≈4.69M aggregated (shared vote/dispo)	n/a	Jun 20, 2025. SEC
  Cormorant Asset Management, LP	5,000,000 (shared vote/dispo)	5.47% (filer calc.)	Aug 14, 2025. Stock Titan
  Prudential Financial, Inc. (umbrella for Jennison/PGIM)	10,391,167 consolidated	7.4%	Aug–Sep 2025. (Umbrella disclosure; overlaps Jennison.) Stock Titan
  Vanguard Group, Inc.	3,450,727	3.83%	Jul 29, 2025. Stock Titan
  BlackRock, Inc.	894,647	~1.0%	Jul 16, 2025. Stock Titan
  (Reference) Company’s SEC page with the full August cluster	—	—	Aug–Sep 2025. Cabaletta Bio, Inc.

  Read-through: Multiple sophisticated, crossover/hedge funds sit near ~10% positions (often with warrants and 9.99% blockers). The concentration provides liquidity/support but also means the cap table can react quickly to data/financing.

  ---

  2) Financials & operating posture (latest reported)

  • Cash & securities: $194.7M at June 30, 2025; company guides runway into 2H 2026. Cabaletta Bio, Inc.+1

  • Burn snapshot: Q2’25 disclosure highlights elevated R&D as registrational prep ramps; (press summary cites R&D ~$37.6M for Q2’25). Stock Titan

  • Capital markets actions: Public offering priced June 11, 2025 (~$100M gross) to extend runway and prep commercial readiness. Cabaletta Bio, Inc.

  • Option repricing (May 2025): Board repriced all outstanding options under 2018/2019 plans to $1.92 (close on May 19, 2025); other terms unchanged; disclosed via 8-K and insider Form 4 footnotes. SEC+3Cabaletta Bio, Inc.+3Cabaletta Bio, Inc.+3

  ---

  3) Technology, clinical status & CMC

  • Modality: Autologous CD19 CAR-T (rese-cel / CABA-201) for autoimmune disease (RESET program: myositis, SLE/LN, systemic sclerosis; also MG & PV studies).

  • Regulatory path: After FDA alignment, company targets a 2027 BLA in myositis; two registrational cohorts (~15 pts each) added to RESET-Myositis (H2’25 start). Cabaletta Bio, Inc.+1

  • Signal recap (EULAR 2025): In myositis, 7/8 patients achieved clinically meaningful TIS responses after discontinuing all immunomodulators and while off/tapering steroids; durability maintained across follow-up in responders. Broader 18-patient dataset (Myositis/SLE/SSc) presented across three orals. Cabaletta Bio, Inc.+1

  • CMC & scale-up: Viral vector Oxford Biomedica; drug product process transferred to Lonza for registrational enrollment; 424B5 also references broader manufacturing network/tech transfer steps. Cabaletta Bio, Inc.+1

  • Fresh materials: Corporate Presentation (Sept 3, 2025) furnished via 8-K; good for latest timelines and site maps. Cabaletta Bio, Inc.+1

  ---

  4) Share-price outlook (2–4 years) — scenario framing

  (Not investment advice; illustrative ranges hinge on efficacy durability, safety, enrollment speed, CMC, and financing.)

  • Bull case (approval path visible): Registrational myositis cohorts reproduce early magnitude/durability with manageable CRS/ICANS; CMC runs clean; payer dialogues constructive. A first-wave autoimmune CAR-T approval narrative can support multi-$bn EV on commercialization math. Catalysts: registrational updates through 2026; BLA prep in 2027. Cabaletta Bio, Inc.+1

  • Base case (solid but mixed): Positive efficacy with some variability; modest timeline slippage; 1–2 additional financings pre-BLA. Stock tracks data cadence and dilution quality. Cabaletta Bio, Inc.

  • Bear case (execution/safety/CMC issues): Durability or safety setbacks in larger N, or CMC friction → regulators request more data; financing at discounts. Shares trade on runway/option value until de-risking. Cabaletta Bio, Inc.

  12–24 mo. watch-items: Registrational cohort initiation/readouts; ≥6–12-mo durability in responders; neurotoxicity/CRS profile with larger N; Lonza/Oxford readiness and yields; net burn vs runway. Cabaletta Bio, Inc.

  ---

  5) Takeover potential & likely interested acquirers

  Is CABA a takeout candidate? Plausible in 12–24 months if registrational myositis data are convincingly positive and safety/CMC are on track. (There is no public report of active talks; this is strategic inference.)

  Most logical buyers (fit rationales):

  • Big Immunology owners: AbbVie, J&J, Roche, Sanofi, GSK — deep autoimmune franchises; acquiring a “one-and-done” CD19 CAR-T for autoimmunity would hedge biologic erosion and extend leadership.

  • Cell-therapy leaders: Novartis, BMS, Gilead — existing CAR-T manufacturing/logistics; diversification from oncology to autoimmunity.

  • Large biotechs seeking autoimmune depth: AstraZeneca, Regeneron — platform integration plus commercial muscle.

  Signals to monitor: expanded CMC partnerships, structured ex-US deals, banker/advisor hires, unusual block trades, and headline registrational efficacy/safety that de-risks approval.

  ---

  6) Key risks (what can break the thesis)

  • Clinical & safety: Autoimmune CAR-T in larger populations is still early; durability and neurotoxicity risk (ICANS) must remain acceptable as N scales; breadth of evidence may be required by regulators. Cabaletta Bio, Inc.

  • Manufacturing & cost-to-serve: Autologous CAR-T economics and logistics vs chronic SOC; execution with Lonza/Oxford is critical for registrational and early commercial phases. Cabaletta Bio, Inc.

  • Financing/dilution: Runway to 2H’26 implies further capital likely ahead of BLA; option repricing aligned incentives but may be viewed as shareholder-unfriendly. Cabaletta Bio, Inc.+1

  ---

  Appendices / source links

  • SEC Filings hub (CABA) — latest 8-K (Sept 3, 2025), DEF 14A (May 13, 2025), Q2’25 10-Q links. Cabaletta Bio, Inc.

  • Q2’25 results PR (Aug 7, 2025) — cash/runway, registrational plan, EULAR data summary, CMC partners. Cabaletta Bio, Inc.+1

  • EULAR 2025 itemized data (Company 8-K & PR) — 7/8 TIS responders off immunomodulators; 18-patient dataset across Myositis/SLE/SSc. Cabaletta Bio, Inc.

  • Manufacturing — Oxford Biomedica (vector), Lonza (drug product) in Q2’25 PR; broader manufacturing/TT in 424B5. Cabaletta Bio, Inc.+1

  • Institutional holders — Bain 13G/A (Aug 14), Adage 13G/A (Aug 12), Alyeska 13G (Aug 14), Jennison 13G (Aug 6), Citadel 13G (Jun 20), Vanguard/BlackRock updates; umbrella PFI. Stock Titan+7Cabaletta Bio, Inc.+7SEC+7

  • Option repricing — Company 8-K (May 15, 2025) and insider Form 4 footnotes (effective May 19, 2025; reset to $1.92). Cabaletta Bio, Inc.+2Cabaletta Bio, Inc.+2

  • Corporate Presentation (Sept 2025) — furnished via 8-K and posted to IR site. Stock Titan+1

  ---

  Bottom line

  Cabaletta has a clear myositis BLA path (2027), supportive EULAR 2025 signals, credible CMC partners, and a cap table populated by sophisticated ~10% holders. Over the next 12–24 months, registrational efficacy/safety + CMC execution will determine whether CABA becomes (a) a high-value independent launch story, or (b) a logical take-out for a large immunology or CAR-T incumbent.

• Ed Note: we are long CABA stock! 

  ---

  🔍 Current Analyst Price Targets

  Source	Avg / Consensus Target	High / Low	Notes
  Fintel	US$11.79 one-year target	High $23.10, Low $2.02 Fintel
  StockAnalysis	US$12.75 average	High $25, Low $2 StockAnalysis
  MarketWatch / Zacks	US$11.56 average / median ~ US$14.00	Low ~US$2.00, High ~US$22.00 MarketWatch+1
  TipRanks	US$12.00 average	High ~US$22.00, Low ~US$2.00 TipRanks
  StocksGuide	US$14.28 average among ~11 analysts	High ~$23.10, Low ~$2.02 StocksGuide
  MarketBeat	US$14.50 consensus	–	Based on 7 buy ratings, 1 hold; upside from current ~$2.18 price MarketBeat

  ---

  💡 What This Implies

  • The consensus range is roughly US$11-$15 under most recent coverage, with outliers up to high-teens or low-$20s in bullish analyst models.

  • The lowest targets are in the $2-$3 range, reflecting some analysts factoring in risk of execution, safety / durability issues, or maybe skeptical timelines.

  • The average upside is very large (several hundred percent) from current share price (~US$2) under many forecasts — which suggests analysts believe a lot of the potential is not yet priced in.

  ---

  ⚙️ Caveats & Reliability

  • Volatility & data risk: Because CABA is clinical-stage, much depends on upcoming data (registrational cohorts, safety, durability). A miss could shift expected targets downward sharply.

  • Wide ranges indicate uncertainty: The $2 lows are likely “if everything goes poorly or delays mount”; the $22+ highs assume strong execution, regulatory alignment, and favorable commercial environment.

  • Time horizon: These are mostly 12-month targets; some assume BLA/registrational success is de-risked sooner. If delays happen, the target may shift.

  • Analyst bias: Some high targets come from firms with more bullish biotech portfolios; they may assume best-case outcomes. Check which analysts have been conservative vs optimistic in similar names.

  
  

Why do Nvidia and so many institutional investors own most of the shares of RXRX - Recursion Pharma

 

Why Nvidia Invested in RXRX

1. Deep AI Integration for Drug Discovery

• In July 2023, Nvidia invested $50 million via a PIPE deal to help Recursion accelerate training of AI models for drug discovery. This investment boosted RXRX stock by about 83% immediately Reuters

• Nvidia provided cutting-edge GPUs and access to its BioNeMo generative-AI cloud platform so Recursion could train models on its massive biological dataset MarketWatch+2.

2. Equity Stake & Strategic Synergy

• Nvidia now holds over 7.7 million shares—approximately a 3–4% stake—making Recursion one of its top non-core holdings The Times+11

• This aligns with Nvidia’s broader strategy of investing in AI-first companies that complement its hardware, not just selling chips.

3. Accelrating RXRX’s Supercomputer Ambitions

• Recursion built BioHive‑2, a supercomputer powered by Nvidia’s DGX H100 GPUs. It delivers a 4x speed increase over their prior system, enabling faster model training Reuters+2T

• This partnership helps validate Nvidia hardware in high-performance biotech applications—which can drive future sales to pharma partners.

---

🏥 Broader Vision: Redefining Pharma with AI

• Recursion uses AI, automation, and robotics to develop drugs more quickly and affordably. Its platform includes the “virtual cell” paradigm and is backed by major pharma companies like Bayer and Roche Investors+14.

• Analysts project RXRX revenue growing at a ~65–73% CAGR through 2027—significantly above typical biotech growth—with Nvidia’s backing lending extra credibility The Motley Fool+5

✅ Summary

Nvidia's investment in RXRX is twofold:

1. Financial Buy-In – it gains exposure to a high-growth biotech using AI and fosters long-term capital appreciation.

2. Strategic Alignment – Nvidia deepens integration of its AI stack (hardware + BioNeMo) in the drug discovery workflow, while demonstrating its systems’ performance in real-world pharma applications.

It’s part of a broader strategy of deploying capital into AI-first companies that can both benefit from and validate Nvidia’s ecosystem, accelerating adoption across industries.

---

Here are the top ten institutional investors in Recursion Pharmaceuticals (RXRX), based on the most recently reported 13F filings (as of March 31, 2025) and aggregated data sources Yahoo Finance+12:

---

🏦 Top 10 Institutional Holders of RXRX

Ranked by percentage ownership:

1. ARK Investment Management LLC — 8.66% (~34.8M shares; ~$184 M) 

2. Vanguard Group Inc. — 8.03% (~32.3M shares; ~$171 M) 

3. Lux Ventures IV LP — 7.46% (~30.3M shares; ~$194 M) 
   

   4. Baillie Gifford & Co. — 6.07% (~24.4M shares; ~$129 M)

4. BlackRock Inc. — 5.78% (~23.5M shares; ~$150 M) 

5. SoftBank Group Corp. — 3.61% (~14.7M shares; ~$94 M) 

6. Kinnevik AB (publ) — 3.30% (~13.4M shares; ~$86 M) 

7. State Street Corp. — 3.22% (~13.1M shares; ~$84 M) 

8. Mubadala Investment Co. PJSC — 3.19% (~13.0M shares; ~$83 M) 

9. Novo Holdings A/S — 2.38% (~9.7M shares; ~$62 M) 

🧾 Summary Table

Investor	% Ownership	Approx. Shares
ARK Investment Management LLC	8.66%	~34.8 M
Vanguard Group Inc.	8.03%	~32.3 M
Lux Ventures IV LP	7.46%	~30.3 M
Baillie Gifford & Co.	6.07%	~24.4 M
BlackRock Inc.	5.78%	~23.5 M
SoftBank Group Corp.	3.61%	~14.7 M
Kinnevik AB (publ)	3.30%	~13.4 M
State Street Corp.	3.22%	~13.1 M
Mubadala Investment Co. PJSC	3.19%	~13.0 M
Novo Holdings A/S	2.38%	~9.7 M

---

💡 Key Insights

• Institutional investors control around 75% of RXRX's outstanding shares Nasdaq+

• ARK and Vanguard are the two largest, with each holding over 8% of the company.

• Lux Ventures IV LP—a prominent insider-linked investor—is effectively the third-largest stakeholder at ~7.5%.

• Other heavyweights include Baillie Gifford, BlackRock, SoftBank, and sovereign/strategic holders like Mubadala and Novo Holdings.

---

Here’s a breakdown of the recent moves by institutional investors in RXRX:

---

📈 Increased Positions (Recent Quarter)

• UBS Asset Management Americas (UBS AM) added 4.15M shares (+183.7%) in Q1 2025 (~$22M) MarketBeat+

• UBS Group AG boosted its stake by 2.57M shares (+85.4%) (~$13.6M) 

• According to CapEdge filings (as of July 22, 2025):

  • KLP Kapitalforvaltning AS increased by +20% (~61K shares)

  • Steel Peak Wealth Management up +21% (~85K shares)

  • Prime Capital Investment Advisors boosted by +61% (~30K shares)

  • IMC‑Chicago surged +76% (~284K shares) 

📉 Reduced or Exited Positions

• RA Capital Management, L.P. fully exited its position, selling 7.73M shares (~$41M) in Q1 2025 

• CapEdge data shows QRG Capital Management reduced its holding by 32% (~19K shares) as of July 21, 2025 

🔍 Additional Context

• Total institutional inflows over the past 24 months reached significantly more than outflows:

  • 83.2M shares purchased (~$550M)

  • 18.3M shares sold (~$117M) MarketBeat

  • This reflects overall upward interest, but pockets of profit-taking and rotation remain.

• Other Q1 fourth-quarter buyers included firms like Brighton Jones, Victory Capital, and Private Advisor Group, while sellers included RA Capital prominently MarketBeatMarketBeat.

---

✅ Summary

• UBS (both global and Americas units) made the largest scale-ups recently.

• RA Capital initiated the most substantial reduction, liquidating its entire stake.

• Mid-cap managers like KLP, Steel Peak, Prime Capital, and IMC‑Chicago also significantly expanded their RXRX positions.

• Some smaller managers, including QRG Capital, reduced or trimmed their positions.

  
  
  

• ED Note:  We are long RXRX